Printer Friendly

BIOMIRA INC. ANNOUNCES REGULATORY APPROVAL FOR CLINICAL TRIALS IN GERMANY

             BIOMIRA INC. ANNOUNCES REGULATORY APPROVAL
                   FOR CLINICAL TRIALS IN GERMANY
    EDMONTON, Alberta, June 15 /PRNewswire/ -- Biomira Inc. (NASDAQ: BIOMF, Toronto, Montreal, Calgary: BRA) today announced that it has received formal regulatory approval to commence clinical trials of its Tru-Scint(R) cancer in vivo diagnostic products in Germany.
    Patient testing will be conducted by oncologists and nuclear medicine specialists at 12 cancer centers and hospitals throughout Germany to determine the safety and efficacy of the products.  These investigations will complement Canadian Phase I/II trials which have been on-going at major cancer institutes since mid-1991.
    In this diagnostic procedure, Biomira's proprietary monoclonal antibody-based agents are labelled with Technetium-99m, a readily available and relatively inexpensive radioisotope.  When injected intravenously, Tru-Scint(R) agents target tumor sites and emit a suitable radiation to pinpoint the size and location of the tumor through visualization on a gamma camera.  This technology is called radioimmunoimaging.
    Three Biomira products will be tested in Germany: Tru-Scint(R) AD(TM) for detecting breast and ovary adenocarcinomas; Tru-Scint(R) SQ(TM) for squamous cell cancers (lung, cervix, head and neck); and Tru-Scint(R) OV(TM) for ovarian cancer.
    Biomira is a public biotechnology firm which has four in vitro test kits on the market under TRUQUANT(R) label for diagnosing gastrointestinal, ovarian, and breast cancers, plus one for measuring the probability of human anti-mouse antibody (HAMA) reaction. Biomira's THERATOPE(R) cancer treatment products are at various phases in the clinical trial process in Canada and the United States. Biomira holds significant interests in H.C.S. Health Care Systems Inc. of Vancouver, and ADI Diagnostics Inc. of Toronto.
    -0-                     6/15/92
    /CONTACT:  Alex McPherson, president and CEO, or A.A. "Tony" Noujaim, senior VP and COO, Immunoconjugate Division, or Jane Jack, of Biomira, 403-490-2812/
    (BIOMF BRA.) CO:  Biomira Inc. ST:  Alberta IN:  MTC SU: KJ -- LA026 -- 0361 06/15/92 17:21 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:313
Previous Article:AMEX'S JAPAN INDEX OPTIONS TRADE MORE THAN 9,500 CONTRACTS
Next Article:THE ZIEGLER COMPANY DECLARES DIVIDEND
Topics:


Related Articles
BIOMIRA ANNOUNCES RESULTS TO JUNE 30, 1992
BIOMIRA INC. ANNOUNCES 3RD QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM LICENSES MELACINE MELANOMA THERACCINE TO BIOMIRA INC. EXCLUSIVELY IN CANADA
BIOMIRA INC. ANNOUNCES COMPLETION OF CANADIAN PUBLIC OFFERING
BIOMIRA INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION
BIOMIRA ANNOUNCES PLANS TO CONDUCT ADDITIONAL PHASE II CLINICAL TRIAL ON TRU-SCINT(R) AD(TM)
Biomira Solidifies Patent Rights for Muc-1 Cancer Antigen
Genetronics Announces Canadian Pharmaceutical, Biotechnology Executive Joins Its Board of Directors
Biomira USA Signs License Agreement with Coulter
Biomira Appoints Vice President of Clinical and Regulatory Affairs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters